Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PB432 vs placebo in acute symptomatic COVID-19 outpatients with new onset cough
2022-003478-22Phase 2Completed
- Sponsor
- Pohl-Boskamp
- Start
- Dec 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing PB432 1200 mg/day with Placebo (2 arms). Primary endpoint: Main efficacy endpoints (eDiary-based). Started Dec 2022; status: completed.
02
Drugs
ELOM-080
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2022-003478-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003478-22.